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Abstract
Background: Traditional genome-wide association studies are generally limited in their ability explain a large
portion of genetic risk for most common diseases. We sought to use both traditional GWAS methods, as well as
more recently developed polygenic genome-wide analysis techniques to identify subsets of single-nucleotide
polymorphisms (SNPs) that may be involved in risk of cardiovascular disease, as well as estimate the heritability
explained by common SNPs.
Methods: Using data from the Framingham SNP Health Association Resource (SHARe), three complimentary
methods were applied to examine the genetic factors associated with the Framingham Risk Score, a widely
accepted indicator of underlying cardiovascular disease risk. The first method adopted a traditional GWAS approach
- independently testing each SNP for association with the Framingham Risk Score. The second two approaches
involved polygenic methods with the intention of providing estimates of aggregate genetic risk and heritability.
Results: While no SNPs were independently associated with the Framingham Risk Score based on the results of
the traditional GWAS analysis, we were able to identify cardiovascular disease-related SNPs as reported by previous
studies. A predictive polygenic analysis was only able to explain approximately 1% of the genetic variance when
predicting the 10-year risk of general cardiovascular disease. However, 20% to 30% of the variation in the
Framingham Risk Score was explained using a recently developed method that considers the joint effect of all
SNPs simultaneously.
Conclusion: The results of this study imply that common SNPs explain a large amount of the variation in the
Framingham Risk Score and suggest that future, better-powered genome-wide association studies, possibly
informed by knowledge of gene-pathways, will uncover more risk variants that will help to elucidate the genetic
architecture of cardiovascular disease.
Background
Cardiovascular disease (CVD), the pathologies associated
with the heart and its vascular structure, are a leading
cause of death worldwide [1]. Many environmental risk
factors exist for the development of CVD, including
smoking, hypertension, diabetes, obesity, as well as per-
sonality characteristics such as competitiveness and a
Type A behavior pattern[2-4]. Previous studies have also
determined that the development of CVD has a strong
genetic component, with heritability estimates ranging
from 38% to 57% [1,5].
Over the past decade, many large-scale efforts have
attempted to find genetic factors associated with CVD
outcomes using single nucleotide polymorphism (SNP)
markers. Several genome-wide association (GWAS) stu-
dies have been successful at identifying genetic variants
associated with CVD and related phenotypes [6]. How-
ever, the effect sizes attributable to these variants have
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results and their respective effect size are shown in
Table 1. Despite strong statistical evidence, the effect
size attributable to any given putative genetic variant is,
at best, modest. These results suggest that while GWAS
studies have had some success, they currently only
explain a very small amount of the genetic risk and her-
itability for many complex phenotypes, including CVD
[7].
The modest number of associated variants found in
previous GWAS studies that, together, explain only a
small amount of variation in risk likely reflects that a
large number of genetic causal variants, each explain-
ing a small amount of risk, contribute to heart disease
[5,8,9]. We refer to this as the “polygenic theory” of
heart disease risk. Recent applications of polygenic
approaches to GWAS data have shown substantial
improvement in the ability to predict disease risk from
common variants [10-12]. In addition, these
approaches have improved our ability to assess the
degree to which these common variants contribute to
the heritability of disease [10,11]. These methods of
polygenic analysis use all SNPs together to examine the
n e te f f e c to fS N P so nd i s e a s er i s k ,i n c l u d i n gl o c io f
small effect that are typically undetectable (given strin-
gent multiple-testing corrections) with traditional asso-
ciation methods [13]. One approach involves
generating a genetic risk score that combines the very
small effects of all non-significant alleles that are indi-
vidually insignificant, but when combined have signifi-
cant predictive ability. Those subjects with higher
genetic risk scores generally have higher risk of disease.
Another approach examines the pairwise genetic and
phenotypic similarity between subjects in a sample, we
then examine if those subjects that have greater genetic
similarity also have greater phenotypic similarity to
each other than is expected by chance. This second
approach estimates heritability due to SNPs by using
SNPs to generate a genetic similarity matrix between
all individuals in the sample. This is analogous to twin
and family methods that estimate heritability based on
assumed degrees of relatedness. The advantage of this
method over the classic twin study approach is that
subjects don’t have to be siblings and instead come
from a sample of unrelated individuals. Another very
important advantage of this method is that family and
twin studies rely on assumptions about the causes of
similarity between family members (e.g., that genes
alone explain the greater similarity of monozygotic
over dizygotic twins). This method avoids these
assumptions due to the fact that subjects do not come
f r o mt h es a m ef a m i l y .F u r t h e r m o r e ,t h ep o l y g e n i ch e r -
itability approach provides information on the fre-
quency spectrum of the causal alleles underlying the
phenotype–something that twin and family methods
cannot do.
Using three different methods of analysis, we show the
extent to which the Framingham Risk Score (an important
CVD-related phenotype) can be predicted using common
genetic variants, as well as how much variation in the phe-
notype can be explained overall using GWAS data.
Methods
GWAS sample
The study sample for this project was derived from the
Framingham SNP Health Association Resource
(SHARe), (version 6) as available through NCBI’sd a t a -
base of Phenotypes and Genotypes (dbGaP). Information
on genotypes (Affymetrix 500 K), phenotypes, family
structure information, and environmental variables were
available in over 9000 participants from three cross-gen-
eration enrollment periods.
Table 1 Summary of gene/locus features identified through GWAS in selected previous studies for CVD related
phenotypes
CVD related
phenotype
Region Reported gene
(s)
Strongest SNP-risk allele from
study
Risk allele
frequency
P-value Effect size Reference
Coronary heart
disease
10p11.23 KIAA1462 rs3739998-C 0.44 1 × 10-11 1.15*[1.11-1.20] [42]
Heart Failure 15q22.31 USP3 rs10519210 0.03 1 × 10-8 1.53*[1.05-2.24] [43]
Mortality with heart
failure
3p22.2 CMTM7 rs12638540-G 0.043 3 × 10-7 1.53*[1.01-2.31] [44]
Coronary heart
disease
3q22.3 MRAS rs9818870-T 0.15 7 × 10-13 1.15 *[1.11-1.19] [42]
Coronary heart
disease
6q25.3 SLC22A3, LPAL2,
LPA
4-SNP haplotype-2 0.02 4 × 10-15 1.82*[1.57-2.12] [45]
Coronary heart
disease
9p21.3 Intergenic rs1333049-C 0.47 3 × 10-19 1.36* [1.27-1.46] [46]
Coronary heart
disease
9p21.3 CDKN2A,
CDKN2B
rs1333049-C 0.47 1 × 10-13 1.47* [1.27-1.70] [7]
The genetic effect refers to the OR and [95% CI]. All listed values are from [6]
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National Heart, Lung and Blood Institute (NHLBI), was
designed to identify common factors that contribute to
risk of cardiovascular disease [14-16]. The FHS has con-
ducted groundbreaking research on CVD outcomes and
is cited as the gold standard for cardiovascular genetic
epidemiology[17,18]. Details on the design and imple-
mentation of the FHS can be found elsewhere [19].
Briefly, 14428 individuals from the town of Framingham,
Massachusetts, were recruited over the course of three
generations. The majority of FHS subjects underwent
extensive physical examinations and lifestyle interviews,
enabling the collection of genetic data along with highly
detailed phenotypic information [19].
Phenotype definition and methods
Framingham Risk Score Calculation
Calculation of the Framingham Risk Score was based on
the methods described by D’Agostino et al. (2008).
Briefly, D’Agostino et al. (2008) developed a risk score
from participants in the Framingham Heart Study to
assess CVD (defined as a coronary death, myocardial
infarction, coronary insufficiency, angina, ischemic
stroke, hemorrhagic stroke, transient ischemic attack,
peripheral artery disease, or heart failure) risk within the
next 10 years. In the present study, this same method
was used to assign risk scores to the current set of parti-
cipants to be used as the phenotypic endpoint. These
scores were calculated for men and women [separately]
using the predictors of: (1) age, (2) HDL, (3) total cho-
lesterol, (4) systolic blood pressure, (5) treatment status
of systolic blood pressure, (6) smoking status, and (7)
diabetic status. See D’Agostino et al. (2008) for a
detailed description of the risk score calculation method
[20]. The calculated regression coefficients for risk score
are presented in table 2.
Complete details on the available data, including
assessment protocols can be found in the Framingham
S H A R ed o c u m e n t a t i o n .W en o t eh e r et h a tb l o o dp r e s -
sure was measured twice at each examination and the
mean of these two measures was used when the partici-
pant had both scores. Cholesterol levels were deter-
mined by standard enzymatic methods while smoking
and hypertensive treatment status was evaluated by par-
ticipant and physician report. Diabetic status was
defined as having definite diabetes (either being treated
for diabetes or having a blood sugar reading of greater
than or equal to 200 mg/dL).
For the original cohort, age, total cholesterol, blood
pressure, smoking and diabetic status were assessed at
Exam 1. HDL levels were not available for this cohort
until Exam 9, making this measure an unusable predic-
tor for risk score of this cohort. Therefore, a mean HDL
level of all remaining participants from Exam 9 was cal-
culated and applied to the original cohort individuals in
conjunction with their Exam 1 scores. All predictors in
the offspring and 3
rd generation cohorts were calculated
from their first exam. With the exception of missing
HDL levels in the original cohort, risk scores were only
calculated for individuals with complete predictor infor-
mation from the first exam.
Genotyping methods and quality control
Traditional GWAS and Polygenic Prediction
Genome-wide genotypes and detailed clinical data on
subjects have been made available to researchers
through the SHARe (SNP-Health Association Resource)
project. Unfiltered genotype data used in our study con-
tained 9236 individuals genotyped for 500,568 SNPs
(from the Affymetrix 500 K mapping array). We used
PLINK, the whole genome association analysis toolset,
in combination with R statistical computing software to
perform quality control procedures [10,21].
Subjects were excluded if genotyping rates were less
than 95%. Individuals were also excluded if the pre-
dicted sex based on X-chromosome genotypes did not
match the recorded sex. Evidence of non-random geno-
typing batch effects was inferred from identity-by-miss-
ingness (IBM) clustering of subjects. A batch covariate
was generated for each subject and used to control for
any batch effects. Subjects who were outliers with
respect to estimated heterozygosity, those greater than 3
standard deviations from the mean, were excluded. All
close relatives of individual subjects, based on mean
identity-by-descent (IBD; PIHAT in PLINK) values indi-
cating relatedness of less than 2
nd degree relatives, were
excluded from the sample. All subjects with an identity-
by-state (IBS) genetic distance from the sample mean of
more than 3 standard deviations were considered out-
liers with respect to genetic ancestry and were pruned
from the sample. This was also confirmed through
visual inspection of Multidimensional scaling (MDS)
Table 2 Regression coefficients used in models
generating Framingham risk scores for 10-year risk of
general cardiovascular disease
Men* Women*
Variable Beta p-value Beta p-value
Log of Age 3.06117 p < .0001 2.32888 p < .0001
Log of Total Cholesterol 1.1237 p < .0001 1.20904 p < .0001
Log of HDL Cholesterol -0.93263 p < .0001 -0.70833 p < .0001
Log of SBP if not treated 1.933303 p < .0001 2.76157 p < .0001
Log of SBP if treated 1.99881 p < .0001 2.82263 p < .0001
Smoking 0.65451 p < .0001 0.52873 p < .0001
Diabetes 0.57367 p < .0001 0.69154 p < .0001
The 10-year risk for women can be calculated as 1-0.95012
exp(ΣbX - 26.1931)
where Beta is the regression coefficient and × is the level for each risk factor;
the risk for men is given as 1-0.88936
exp(ΣbX - 23.9802) [20]
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were less than 95%, (2) minor allele frequencies were
less than 0.01, and (3) if p-values from the Hardy-Wein-
berg Equilibrium (HWE) test were less than 1 × 10
-4.
Evidence of non-random genotyping failure was exam-
ined, as inferred by flanking haplotypic background and
significant markers were excluded (PLINK mishap test,
p<1×1 0
-6). We also removed individuals who had
missing values for any covariates or phenotypic data.
After quality controls, the remaining sample consisted
of 1772 individuals genotyped on 258891 SNPs.
Polygenic Heritability Analysis
To minimize the chance that our polygenic heritability
findings could be due to confounders (e.g., SNP batch
effects) we used additional, very stringent quality control
procedures for this analysis, as suggested in [11]. Only
those quality control methods that differ from those
detailed above are listed below; otherwise all previously
mentioned quality control procedures and generation of
covariates were the same.
Markers were excluded if p-values from HWE tests
were less than .05. Evidence of non-random genotyping
failure was examined, as inferred by flanking haplotypic
background and significant markers were excluded
(PLINK mishap test, p < 1 × 10
-10)[11]. Subjects were
excluded if genotyping rates were less than 99%. All
close relatives of individual subjects, based on pairwise
IBD (PIHAT) values greater than .025, were excluded
from the sample when the GCTA software package was
used to estimate heritability. We also removed indivi-
duals who had missing values for any covariates or phe-
notypic data. After quality controls, the remaining
sample consisted of 1270 individuals genotyped on
250378 autosomal SNPs.
The polygenic heritability method involves first calcu-
lating the pairwise relatedness from SNPs between all
individuals in a sample. When using the GCTA software
package, any subjects that were related to any other sub-
ject with a degree greater than .025 IBD were dropped
from the analysis altogether. This resulted in a signifi-
cant loss of sample size (from 6725 to 1270) and thus a
large reduction in power and an increase in standard
error of the heritability estimate. To circumvent this
large drop in sample size, we utilized an additional
method of estimating heritability from pairwise related-
ness based on a Haseman-Elston (H-E) regression fra-
mework [21]. In a traditional H-E regression analysis,
genetic relatedness is based on knowledge of pedigree
and is regressed on trait difference between twins (either
MZ or DZ). This generates an estimate for how much
genetic similarity predicts phenotypic similarity. Our
method uses a conceptually similar approach, but
instead of using pedigree information, SNPs are used to
determine the degree of genetic similarity between
unrelated individuals. Using H-E regression, only those
individual pairwise comparisons > .025 IBD (rather than
entire subjects) were removed. This allows for the
genetic relatedness information from all comparisons
between subjects (other than those between close rela-
tives) to be utilized in the analysis. Due to the non-inde-
pendence between pairwise comparisons (the pairwise
relationships from the same person are not independent
of one another), we used bootstrapping to determine all
significance levels and confidence intervals for H-E
regression results. After quality controls, the sample
used in the H-E regression analysis consisted of 6725
individuals genotyped on 250378 autosomal SNPs.
Statistical analysis methods
We performed three methods of genome-wide analysis
using population-based methods. For all analyses, a
logarithmic transform of the cardiovascular disease phe-
notype score ensured that outliers in the data did not
have unusual leverage on the estimates of our analyses,
as well as preventing the assumption of normally dis-
tributed errors from being violated [22]. Analysis was
also performed on untransformed data and effectively
resulted in all of the same conclusions presented.
Traditional GWAS
Initially a traditional GWAS analysis was performed on
all SNPs using Framingham risk score as the target phe-
notype. Using the PLINK software package (v1.07) with
the linear models option, a multiple linear regression
test was performed on all quality controlled SNP data
using 1772 individuals [10]. An additive mode of inheri-
tance was assumed and empirical p-values were gener-
ated for association with the quantitative phenotype at
each locus after controlling for age, sex, genotyping
batch effects, and (to control for the effects of popula-
tion stratification) the 20 most significant principal com-
ponents. A Manhattan plot and a Quantile-Quantile (Q-
Q) plot were used to visualize association results. Prior
to the analysis, we adopted the genome-wide signifi-
cance threshold of p < 5 × 10
-8 to account for multiple
testing [23]. SNP call intensities were examined to
determine whether significant SNPs were aberrations
caused by poor quality genotyping. Significant SNPs
within single genes based on NCBI Build 36.3 were then
examined in Entrez Gene and PubMed to determine if
any of these genes had previous associations with phe-
notypes thought to be related to cardiovascular disease.
Polygenic Prediction
Our second approach used a predictive polygenic model
that effectively estimates the ability of common variants
to predict the phenotypic score. Polygenic inheritance is
expected to apply to many complex traits, CVD not
withstanding [24]. Thousands of small effects that are
indistinguishable from background noise when
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for a large proportion of the risk variation. Given the
available sample size, we used a 10 fold cross-validation
technique to minimize any effects of sampling error on
polygenic prediction estimates [25]. Methods of cross-
validation are commonly used when the intent is to esti-
mate how accurately a prediction model will perform
with minimal bias due to the sampled data [26]. This
method involved partitioning the data from subjects into
10 discovery and test sets respectively. Each discovery
set consisted of 90% of the individuals (N = 1575) from
the total data set, while each test set consisted of the
remaining 10% of subjects. Each of the 10 test sets was
composed of a different 10% of the sample, thus no
overlap between any of the test sets existed. For each
discovery set, a GWAS analysis was performed [27].
Using the results from this discovery phase, subsets of
SNPs composed of those with p-values in the ranges of
> .9-1, > .8-.9, > .7-.8, > .6-.7, > .5-.6, > .4-.5, > .3-.4, >
.2-.3, > .1-.2, > 0-.1 were generated [13]. The rationale
behind grouping subsets of SNPs in ascending 0-.1 p-
value bins is to verify the assumptions of a model where
many SNPs of small effect are major contributors to
CVD risk. With the current sample size, power to detect
variants of small effects is individually very low, and by
relaxing significance thresholds, power to detect com-
mon variants with small effect sizes increases (with a
concomitant rise in number of false associations). SNPs
from the discovery set in the lower p-value bins should
o na v e r a g eh a v em o r ep r e d i c t i v ea b i l i t yt h a nt h o s ei n
the higher p-value bins, due to the higher ratio of true
associations to type I errors [27].
Using the corresponding independent test set (the
remaining 10%, N = 175), a genotypic risk score profile
was assigned to each individual that represents the net
predictive effect of all reference alleles possessed by a
given individual. These genotypic risk scores were calcu-
lated using PLINK’s SNP scoring routine. Each indivi-
dual’s score was calculated by summing the number of
reference alleles at each locus multiplied by the value of
the Beta for that respective SNP, which were generated
from the initial survey of the discovery set [10,13,27].
Linear regression was then used to assess the relation-
ship between risk of cardiovascular disease and the con-
structed polygenic risk scores in the test group [26].
This same procedure was iterated for each of the 10
sample hold outs, allowing an unbiased estimate (in
terms of r
2) of the ability of common SNPs to predict
the Framingham Risk Score.
Polygenic Heritability Analysis
Our third approach used two methods (restricted maxi-
mum likelihood and H-E regression) to estimate the
proportion of the variance in the Framingham Risk
Score that is explained by the common SNPs from the
FHS data set. Instead of trying to predict heart disease
risk from genotype, we examined if similarity in pheno-
type was significantly predicted by similarity of geno-
type. We examined if those subjects whose genomes are
more similar than is expected by chance also have phe-
notypes that are more similar than is expected by
chance. Using the GCTA software package [28], a
genetic relationship matrix was generated based on
shared combinations of SNPs and weighted by allele fre-
quency. Then a linear model was fit to these genetic
relationships using either a) a restricted maximum likeli-
hood (REML) estimation maximization algorithm, as
implemented in GCTA, or b) a linear regression model
based on a H-E regression framework to estimate the
variance explained by common SNPs [28].
Results and Discussion
Traditional GWAS
No individual SNPs were associated with Framingham
Risk Score at a genome-wide level of significance after
controlling for all covariates. The ten independent SNPs
that achieved the lowest p-values (above the significance
threshold) are shown in table 3. We further investigated
these most significant SNPs to look for any evidence of
replication of previous findings. Four of the top ten
most significant SNPs were in regions directly associated
with CVD or related phenotypes based on previous
research. These SNPs are highlighted in table 3.
The SNP rs17051776, located within the gene NBEA
has been previously reported to be associated with
blood lipid levels [29]. A strong association was found
for SNP rs1862523, which is flanking the 5’ end of the
gene NPR3. NPR3 has been previously reported to be
associated with ventricular dysfunction, blood pressure
in obesity-associated hypertension [30], as well as a
family history of hypertension and cardiovascular disease
[31]. The final two SNPs - rs2111202 and rs12611756,
are in genes that have been previously reported to be
associated with smoking, another factor contributing to
Framingham Risk Score [32,33].
Polygenic Prediction
Two of the ten examined SNP sets (binned by p-values)
were able to significantly predict the Framingham Risk
Score phenotype, with a third set just missing statistical
significance. This suggests a polygenic etiology underly-
ing CVD (as measured via the Framingham Risk Score),
as well as the existence of a number of relevant risk var-
iants of small effect across the allele frequency spectrum
(see Table 4). While the effect of any single SNP could
not be discerned from random noise in the initial
GWAS, the combined predictive ability of many SNPs
based on score sets provides evidence that some of the
risk for CVD is due to common SNPs. The ranges of
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values where true associations are maximized relative to
the number of type I errors (signal to noise maximiza-
tion). While a weak overall trend of greater predictive
ability is observed as the p-value range of the SNP set
becomes more stringent, excessive noise is likely to
blame for the apparent lack of this effect in some of the
more stringent bins (> .3-.4, > .1-.2, > 0-.1). As expected
with a sample of this size, the predictive ability of any
SNP set is poor, due in large part to the small number
of true associations relative to type I errors in the dis-
covery set across allele frequencies. Examination of the
Quantile-Quantile (Q-Q) plot from the initial GWAS
confirms that few associations diverge from what is
expected by chance, explaining both the general unifor-
mity in number of SNPs in each SNP set, as well as the
generally weak predictive ability of each set.
Polygenic Heritability Analysis
A linear model was fit to the CVD data using a
restricted maximum likelihood (REML) estimation
maximization algorithm to estimate the variance
explained by common SNPs. This was done three times
using comparable algorithms for REML iterations within
the GCTA software package. These REML algorithms
included 1.) Average Information, 2.) Fisher-scoring, and
3.) Estimation Maximization; all three resulted in
approximately the same genetic variance being
explained, with heritability estimates between 31% and
3 4 % ,a si ss h o w ni nT a b l e5 .H o w e v e r ,n o n eo ft h e s e
three estimates were significantly different from zero
due to the large standard errors around the estimates.
As explained above, the REML analysis used data from
only 1270 subjects, limiting the power of this approach.
T ou t i l i z em o r eo ft h ed a t aa n di m p r o v ep o w e rt o
detect heritability, we also used a linear regression
model based on the H-E regression framework to esti-
mate the variance explained by common SNPs [28].
Heritability due to common SNPs was estimated at 18%.
Empirical standard error estimates for genetic variance,
phenotypic variance, and p-values were all determined
using a bootstrapping re-sampling procedure. Due to
the much larger sample size used with the H-E regres-
sion algorithm, the estimates provided by this model
have much smaller standard error than those provided
using the REML approach and give a significant esti-
mate for the heritability of cardiovascular disease due to
common SNPs (p = .026) as can be seen in Table 5.
Conclusions
The aim of this study was to use recently developed
methods of polygenic analysis in conjunction with tradi-
tional GWAS methods to identify SNPs that may be
involved in the risk of CVD, to understand how well
CVD can be predicted from using all SNPs, and to esti-
mate the variance explained in CVD risk when consider-
ing all SNPs together. Using data from the FHS, we
performed complimentary methods of analysis examin-
ing the genetic factors contributing to Framingham Risk
Score, a widely accepted indicator of CVD risk. The use
Table 3 Ten most significant SNPs associated with Framingham Risk Score using GWAS
SNP Rank SNP ID Region Gene Beta P-value
1 rs17584191 5q23.2 Intergenic; flanking LMNB1 0.09579 1.866e-05
2 rs17051776 13q13 NBEA -0.28380 2.987e-05
3 rs483487 3q26.31 NLGN1 0.11820 3.239e-05
4 rs215935 6q14-q15 Intergenic; flanking TBX18 -0.08192 4.258e-05
5 rs1862523 5p14-p13 Intergenic; flanking NPR3 -0.08753 4.610e-05
6 rs2111202 7q3 NRCAM 0.09009 5.237e-05
7 rs12611756 2p12-p11.1 CTNNA2 0.08251 5.875e-05
8 rs1491609 3p13 Intergenic; flanking FOXP1 -0.08143 5.952e-05
9 rs1346949 18q21.33 Intergenic; flanking PIGN -0.08592 6.730e-05
10 rs17205291 1q42 Intergenic; flanking KIAA1804 0.10680 6.860e-05
No single SNP was significant at the genome-wide level after multiple testing correction. SNPs that appear to replicate previous findings are highlighted.
Table 4 The number of scoring SNPs that fall into each
p-value threshold based on the discovery set is shown.
Target GWAS Statistics for Each Scoring SNP Set
P-Value Threshold
Range
Number of
SNPs
P-Value Adjusted
R
2
> 0-.1 24843 0.4974 0
> .1-.2 24201 0.8096 0
> .2-.3 24329 0.00393* 0.004177
> .3-.4 23962 0.971 0
> .4-.5 24269 0.032033* 0.002056
> .5-.6 24500 0.06449 0.001383
> .6-.7 24429 0.7129 0
> .7-.8 24429 0.23410 0.0002382
> .8-.9 24397 0.444 0
> .9-1 24508 0.7921 0
Significant ranges and their respective p-values are highlighted.
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sample of related individuals and subsequent bootstrap-
ping to estimate heritability and standard errors repre-
sents a novel advance that can be utilized in other
samples where individuals are highly related [25,26,28].
Due to linkage disequilibrium, genotyped SNPs tag
other, unobserved, variants in the genome. Some have
argued that when certain SNP appears to be associated
with a disease, it is possible that the SNP itself is not
the causal variant [34]. The hypothesis that synthetic
association, the process described in the previous sen-
tence, represents a significant portion of the common
variant associations observed in the literature today, has
been shown to be a very unusual occurance [35]. Given
s y n t h e t i ca s s o c i a t i o n sa r en o tt h ed r i v i n gf o r c eb e h i n d
the majority of disease associated SNPs in the genome,
the polygenic methods employed in this paper, used for
both estimation of risk and heritability, provides the first
evidence that a substantial proportion of the heritability
underlying CVD is due to common causal variants. The
results of this study show that SNPs predict a small but
statistically significant amount of the genetic risk for
CVD (as measured via the Framingham Risk Score).
Although our results provide compelling evidence for
the polygenic structure of the genetic architecture
underlying CVD, it does not pinpoint where these risk
variants reside within the human genome. Nevertheless,
the top SNPs identified in the initial GWAS performed,
and the genes in which they reside, merits further inves-
tigation. One way to further inform predictive polygenic
analysis would be to include SNPs that lie within genes
and pathways when grouping SNPs into predictive SNP
sets. Gene and pathway-based prediction would examine
the predictive utility of a group of genetic variants that
all belong to the same biological pathway [36]. This
method of predictive analysis could help to give a more
holistic perspective of the underlying structure of CVD
and evaluate the contribution of different biological pro-
cesses and systems to disease risk [37]. Many SNPs that
appear to be insignificant when examined indepen-
dently, or uninformed sets that are weakly predictive of
disease state, could be highly significant and predictive
when examined as a set composed of SNPs from genes
that work in concert within a pathway [38]. An example
of the success of pathway based analysis when applied
to GWAS is shown by a recent article where the under-
lying pathways of 11 diseases are examined and strong
findings and replication are observed [39].
Given the small effect sizes of common genetic var-
iants, GWAS studies will have to assemble larger sample
sizes in order to identify true genetic association signals
arising for individual SNPs. For example, Yang et al
(2010)[11] conducted a GWAS involving approximately
1 8 0 , 0 0 0s u b j e c t sw h e r et h e yw e r ea b l et oe x p l a i n
approximately 10% of the genetic variance in height
while simultaneously identifying the significant loci that
contribute to this estimate. As sample sizes increase, the
power to detect small effects increases. Although the
detected polymorphisms may explain little variation
individually, with large sample sizes, their cumulative
effect should increase, and through pathway analysis
and consideration of gene families, such studies can pro-
vide important insight into the genetic architecture
underlying traits. Similar conclusions have been drawn
from recent studies involving the polygenic structure of
height as well as schizophrenia [10,11].
One of the weaknesses of the present study was the
modest sample sizes (see table 5) used for the GWAS,
the polygenic risk score analysis, and the estimation of
heritability using the maximum likelihood approach. As
explained above, larger sample sizes than the one cur-
rently used are needed to detect small effects sizes likely
to underlie the genetic variation in CVD. Similarly, it is
likely that the ability to predict CVD using SNPs will
improve measurably with larger sample sizes, as recently
shown to be the case in schizophrenia [10]. The ability
to predict a significant portion of disease risk from gen-
otype can result in early intervention and improved
treatment. Identification of a molecular profile could be
a useful tool for prevention and management of CVD
and related disorders [40].
CVD is a complex, highly polygenic disease that is one
of the leading causes of death worldwide. This study has
demonstrated novel approaches to investigate heritability
due to SNPs in samples where individuals are unrelated
and has also shown that SNPs can be used to predict
Table 5 Results of Linear Model analysis using 4 algorithms to estimate heritability V(g)/Vp
AI Algorithm Fisher Algorithm EM Algorithm HE Regression Algorithm
Source Variance SE Variance SE Variance SE Variance SE P-value
V(g) 0.000668 0.000569 0.000668 0.000551 0.000727 0.000552 0.250341 0.133737
Vp 0.002151 0.000087 0.002151 0.000086 0.002152 0.000087 1.354157 0.015038
V(g)/Vp 0.310483 0.263126 0.310483 0.254964 0.337865 0.25492 0.184869 0.098453 0.026*
logL 3222.103 3222.103 3222.098
n 1270 1270 1270 6725
Algorithm type and their respective heritability estimates and standard errors are highlighted.
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Page 7 of 9CVD. We also provide evidence strongly consistent with
the polygenic theory of CVD and show that much of
the genetic variation underlying CVD is likely to be due
to common causal polymorphisms. Based on these
results, we conclude that there remains much informa-
tion in, and much to be learned by the continued use of
SNP panels in the investigation of cardiovascular pheno-
types as well as other human diseases. Through the use
of these methods in future studies, a better understand-
ing of disease, and improved clinical outcomes are
achievable [41].
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